论文部分内容阅读
目的观察血塞通+地塞米松+尿激酶治疗糖尿病下肢深静脉血栓的临床疗效。方法将25例患者随机分为治疗组14例选用血塞通+地塞米松+尿激酶治疗,对照组11例单用尿激酶治疗,治疗前后对患者各进行一次血液流变学、彩色超声多普勒检查。结果治疗组疗效及再通率优于对照组(P<0.05),两组治疗后血液流变学指标均有改善,而治疗组明显优于对照组(P<0.01)。结论血塞通+地塞米松+尿激酶能降低血液黏度、改善血液流变性,对糖尿病下肢深静脉血栓形成有较明显疗效,且安全可靠,是治疗糖尿病下肢深静脉血栓形成的有效药物。
Objective To observe the clinical efficacy of Xuesaitong + dexamethasone + urokinase in the treatment of diabetic lower extremity deep venous thrombosis. Methods Twenty-five patients were randomly divided into treatment group (14 cases), Xuesaitong + dexamethasone + urokinase group (11 cases) and urokinase group (control group). Hemorheology, color ultrasound Pule check. Results The curative effect and recanalization rate of the treatment group were better than those of the control group (P <0.05). The indexes of hemorheology were improved in both groups, but the treatment group was better than the control group (P <0.01). Conclusion Xuesaitong + dexamethasone + urokinase can reduce blood viscosity, improve blood rheology, has a significant effect on diabetic lower extremity deep vein thrombosis, and safe and reliable, is an effective drug for the treatment of diabetic lower extremity deep vein thrombosis.